10-Q: Baxter International Reports Q1 2025 Results, Sale of Kidney Care Business Drives Earnings

Baxter International's Q1 2025 results show increased net income driven by the sale of its Kidney Care business, despite ongoing supply chain challenges and macroeconomic uncertainties.

Summary

• Baxter International Inc. reported net sales of $2.625 billion for the quarter ended March 31, 2025, compared to $2.490 billion for the same period in 2024.
• Net income attributable to Baxter stockholders was $126 million, or $0.25 per diluted share, compared to $37 million, or $0.07 per diluted share, in the prior year.
• The company completed the sale of its Kidney Care business to Carlyle for $3.80 billion in cash on January 31, 2025, recognizing a pre-tax gain of $191 million ($111 million net of tax).
• The company repaid $3.13 billion of shortand long-term indebtedness primarily with the net after-tax cash proceeds from the sale of its Kidney Care business.
• Baxter experienced significant challenges to its global supply chain, including production delays, increased costs, and shortages of raw materials.
• The company recorded $98 million of pre-tax net charges related to remediation, air freight, and other costs as a result of damages caused by Hurricane Helene.
• Baxter expects to incur additional pre-tax costs of approximately $4 million related to the implementation of business optimization programs.
• The company's effective income tax rate differs significantly from the 21% U.S. federal statutory rate due to various factors, including foreign rate differences and tax incentives.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the sale of the Kidney Care business boosted earnings, the company faces ongoing challenges related to supply chains, macroeconomic uncertainty, and regulatory pressures. The impact of Hurricane Helene and the need for cost savings initiatives also contribute to a mixed outlook.

Positives

• The sale of the Kidney Care business significantly boosted net income and provided substantial cash proceeds for debt reduction.
• Medical Products & Therapies segment net sales increased 3% in the first quarter of 2025.
• Healthcare Systems & Technologies segment net sales increased 6% in the first quarter of 2025.
• Pharmaceuticals segment net sales increased 1% in the first quarter of 2025.
• Debt repayments in the first quarter of 2025 and the fourth quarter of 2024 decreased interest expense.

Negatives

• Supply chain challenges, including production delays and increased costs, continue to impact operations.
• Hurricane Helene caused significant damage and resulted in $98 million in pre-tax charges.
• The company expects to incur additional costs related to business optimization programs.
• The Kidney Care MSA sales favorably impacted sales growth by 3% and the exit of IV solutions in China adversely impacted sales by 1%.

Risks

• Global supply chain disruptions, including shortages of raw materials and increased transportation costs, pose ongoing challenges.
• Macroeconomic uncertainty, including trade policies and tariffs, could adversely affect the company's business and financial condition.
• Regulatory risks, including potential actions by the FDA and other government agencies, could impact product development, manufacturing, and sales.
• The company faces potential litigation and legal proceedings, including product liability and environmental matters.
• The company's ability to generate cash flows from operations and access capital markets could be affected by various factors, including demand for its products and credit ratings.

Future Outlook

Baxter expects some hospital customers to continue a level of fluid conservation during 2025 with the impact waning over the course of the year as product allocations are lifted. The company continues to pursue cost savings initiatives, including those intended to mitigate a portion of the dis-synergies that arose as a result of the sale of our Kidney Care business, and to the extent further cost savings opportunities are identified, we would incur additional restructuring charges and costs to implement business optimization programs in future periods.

Industry Context

The healthcare industry is facing ongoing supply chain challenges, macroeconomic uncertainties, and regulatory pressures, impacting companies like Baxter. The company's strategic actions, including the sale of the Kidney Care business, reflect a broader trend of portfolio optimization and focus on core growth areas within the medical products and therapies, healthcare systems and technologies, and pharmaceuticals sectors.

Comparison to Industry Standards

• It is difficult to compare Baxter's results directly to industry standards without specific competitor data.
• However, companies like Medtronic, Johnson & Johnson, and Abbott also operate in the medical device and healthcare space and face similar challenges related to supply chains, regulatory compliance, and market competition.
• Baxter's strategic decision to divest its Kidney Care business is similar to actions taken by other large healthcare companies to streamline operations and focus on higher-growth segments.
• The $98 million impact from Hurricane Helene is a unique event, but other companies in the manufacturing sector are also exposed to risks from natural disasters and severe weather events.

Legal Proceedings

• The company is involved in product liability, patent, commercial, employment and other legal matters that arise in the normal course of our business.
• In March 2020, two lawsuits were filed against us in the Northern District of Illinois by plaintiffs alleging injuries as a result of exposure to ethylene oxide used in our manufacturing facility in Mountain Home, Arkansas to sterilize certain of our products.
• Since December 2023, 41 lawsuits (after giving effect to the September 2024 amendment referenced below) have been filed against us in the Circuit Court of Cook County, Illinois by plaintiffs alleging injuries as a result of exposure to ethylene oxide used by several companies, including historic use by us for sterilization at our facility in Round Lake, Illinois.
• In July 2021, Hill-Rom, Inc., a wholly-owned subsidiary of Hillrom, received a subpoena from the United States Office of Inspector General for the Department of Health and Human Services (the DHHS) requesting documents and information related to compliance with the False Claims Act and the Anti-Kickback Statute.
• In October 2022, the DOJ issued a separate Civil Investigative Demand (CID) addressed to Hillrom, requesting documents and information related to compliance with the False Claims Act and the Anti-Kickback Statute.
• On December 28, 2021, Linet Americas, Inc. (Linet) filed a complaint against Hill-Rom Holdings, Inc., Hill-Rom Company, Inc., and Hill-Rom Services, Inc. in the United States District Court for the Northern District of Illinois, captioned Linet Americas, Inc. v. Hill-Rom Holdings, Inc.; Hill-Rom Company, Inc.; Hill-Rom Services, Inc.
• On June 20, 2024, Reading Hospital filed a putative class action complaint against Hill-Rom Holdings, Inc., Hill-Rom Company, Inc., and Hill-Rom Services, Inc. in the United States District Court for the Eastern District of Pennsylvania.

Stakeholder Impact

• Shareholders will see increased earnings per share due to the sale of the Kidney Care business.
• Employees may be affected by cost savings initiatives and restructuring programs.
• Customers may experience disruptions due to supply chain challenges and the impact of Hurricane Helene.
• Suppliers may be affected by changes in sourcing and procurement strategies.
• Creditors will benefit from the company's debt reduction efforts.

Next Steps

• The company expects to use substantially all of the remaining net after-tax proceeds to continue to repay indebtedness through the second quarter of 2025.
• Baxter will continue to evaluate the impact of legislative changes as additional guidance becomes available.
• The company will continue to pursue cost savings initiatives, including those intended to mitigate a portion of the dis-synergies that arose as a result of the sale of our Kidney Care business.

Key Dates

Keywords

Baxter International, Kidney Care, Financial Results, Q1 2025, Net Sales, Net Income, Supply Chain, Hurricane Helene, Debt Repayment, Pharmaceuticals, Medical Products, Healthcare Systems, Strategic Actions, Operating Model, Restructuring